Your browser doesn't support javascript.
loading
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Basho, Reva K; Gilcrease, Michael; Murthy, Rashmi K; Helgason, Thorunn; Karp, Daniel D; Meric-Bernstam, Funda; Hess, Kenneth R; Herbrich, Shelley M; Valero, Vicente; Albarracin, Constance; Litton, Jennifer K; Chavez-MacGregor, Mariana; Ibrahim, Nuhad K; Murray, James L; Koenig, Kimberly B; Hong, David; Subbiah, Vivek; Kurzrock, Razelle; Janku, Filip; Moulder, Stacy L.
Afiliação
  • Basho RK; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
  • Gilcrease M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston.
  • Murthy RK; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Helgason T; Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston.
  • Karp DD; Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston.
  • Meric-Bernstam F; Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston5Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston6Breast Surgical Oncology, The University o
  • Hess KR; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
  • Herbrich SM; Pediatrics, The University of Texas MD Anderson Cancer Center, Houston.
  • Valero V; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Albarracin C; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston.
  • Litton JK; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Chavez-MacGregor M; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston9Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.
  • Ibrahim NK; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Murray JL; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Koenig KB; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Hong D; Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston.
  • Subbiah V; Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston.
  • Kurzrock R; Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston10Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla.
  • Janku F; Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston.
  • Moulder SL; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston4Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston.
JAMA Oncol ; 3(4): 509-515, 2017 Apr 01.
Article em En | MEDLINE | ID: mdl-27893038
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Neoplasias de Mama Triplo Negativas / Bevacizumab Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Neoplasias de Mama Triplo Negativas / Bevacizumab Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article